The U.S. FDA has warned Allergan Inc. that the Web site for its eyelash thickener Latisse is misleading. The site downplays or fails to mention risks associated with the product.
The Latisse site either doesn't mention potential side effects including bacterial eye infections, allergic reactions, excess hair growth outside the intended treatment area, and permanent changes in iris and eyelid pigmentation, or presents them in very small text.
The drug is approved to make eyelashes thicker, fuller and darker. Latisse, or bimatoprost, was already on the market as a treatment for glaucoma.